About the Journal

FOCUS AND SCOPE

It is the policy of the Pakistan Journal of Pathology (PJP) to publish articles pertaining to Pathology providing sufficient contribution to medical knowledge. The journal is presently being published quarterly. The articles may include, original research, review articles, case reports, retrospective analysis of data, and new experimental methods of medical importance. PJP is a peer-reviewed journal that considers articles on all aspects of histopathology, hematology, chemical pathology, microbiology, virology, and immunology. It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge.

PEER REVIEW PROCESS

Peer review is the critical assessment of manuscripts submitted to journals by experts who are not part of the editorial staff. Peer review can, therefore, be viewed as an important extension of the scientific process. It is the policy of PJP that every article received for the publication is peer-reviewed by at least two senior specialists of the concerned specialty. The "double-blind" process is strictly followed. PJP operates an 'open peer review' policy meaning reviewers are asked to sign their reviews. In certain controversial cases, the opinion of a 3rd reviewer is also obtained. In case of conflict of opinion between the two reviewers, the matter is referred to the Chief-editor.

OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. As per Open Access policy of Pak J Pathol, copyright holder of a scholarly work grants usage rights to others using an open license (Creative Commons or equivalent) allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose.

 COPYRIGHT STATEMENT

Any article submitted to Pak J Pathol must not be previously submitted to any other journal and must not be published in part or total. The authors will be requested to sign an agreement to give copyright to the publishers. The authors will also be requested to assist the editors in final proof reading of their articles before publication.

  • On submitting article to Pak J Pathol we agree that all copyright ownership is transferred to the Pak J Pathol even the article can be declined after the acceptance as per decision of the Editorial Board.
  • All the content available on Pak J Pathol website is the property of Pak J Pathol if created by Pak J Pathol, or of the person or entity who or which owned it prior to submission to Pak J Pathol. 

 DATA SHARING POLICY  

Pak J Pathol has policy on data sharing. We require that the data generated by research supporting the article be made openly and publicly available upon publication of article.  Pak J Pathol require data from clinical trials to be made available upon reasonable request.

Clinical trials that begin enrolling participants on or after 1 January 2019 must include a data sharing plan in the trial's registration according to the ICMJE's policy regarding trial registration. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.

Data sharing statements indicates the following: whether individual deidentified participant data (including data dictionaries) what data in particular is shared; whether additional, related documents is available (e.g., study protocol,  informed consent form, statistical analysis plan, clinical study report etc.); when the data is available and for how long; by what access criteria data is shared (including with whom, for what types of analyses, and by what mechanism). Data are available indefinitely immediately after publication of article. 

 PLAGIARISM AND DATA FABRICATION 

Plagiarism is not acceptable in Pakistan Journal Pathology. Plagiarism includes copying text, ideas, images, or data from another source, even from own publications, without giving credit to the original source.

If plagiarism is detected during the initial editorial triage, the manuscript may be rejected.
It is the policy of editorial committee of Pak J Pathol to blacklist any author found to be guilty of plagiarism. The name of author(s) committing plagiarism will also be disseminated to editors of other medical journals, PMC and HEC. Data presented must be original and not inappropriately selected, manipulated, enhanced, or fabricated. This includes

1)         Exclusion of data points to enhance significance of conclusions,

2)         Fabrication of data

3)         Selection of results that support a particular conclusion at the expense of contradictory data,

4)         Deliberate selection of analysis tools or methods to support a particular conclusion.

REPOSITORY POLICY 

Author Self-Archiving Policy

As Pak J Pathol is an Open Access journal authors are entitled to make their article publicly available according to the terms of the CC BY license:

  • CC BY-NC
  • Authors who have published under a CC BY-NC 4.0 license may share and distribute their article on non-commercial websites and repositories.

 Re-use guidelines for open access content

When posting, distributing or reusing Open Access articles, the journal should be clearly attributed as the original place of publication and correct citation details should be given. Authors should also deposit the URL of their published article in any repository, in addition to the Version of Record.

When making their article available according to the terms of their Open Access license, we strongly encourage authors to deposit the Version of Record. This will guarantee that the definitive version is readily available to those accessing your article from such repositories and means that your article is more likely to be cited correctly.

EDITORIAL POLICY

The Journal takes great care to secure the confidentiality and integrity of the peer-review process; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or journal editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at [email protected].

In general, the manuscript should not already have been formally published in any journal or in any other citable form. In any case where there is the potential for overlap or duplication we require that authors are transparent. Authors should declare any potentially overlapping publications on submission.

AUTHORSHIP

Submission of a manuscript to a PJP implies that all authors have read and agreed to its content and that the manuscript conforms to the journals policies. Only six authors are allowed in a single institution / single discipline study.  In a multi-institution / multi-disciplinary and international collaboration research, Editorial Board shall guide on an individual case basis. Each author is expected to have made substantial contributions to the conception OR design of the work; OR the acquisition, analysis, OR interpretation of data; OR the creation of new software used in the work; OR have drafted the work or substantively revised it. Contributors who do not meet the above criteria for authorship, but helped in the study, may be listed in the acknowledgment section. Examples of those who might be acknowledged include a person who provided purely technical help or writing assistance, or a department chair who provided only general support.

When submitting a manuscript to the PJP, the corresponding author takes responsibility on behalf of all authors for the authorship, authenticity, and integrity of the research being reported. The corresponding author should be available throughout the submission and peer review process to respond to editorial queries in a timely way, and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions about the paper arise after publication.

A current and functional email address needs to be provided for each author at submission. Authors added at revision also need an email address provided in the system. Any change made to the list of authors (addition, removal, change in order) after manuscript acceptance requires consent of all authors and editorial approval.

Statements describing detailed contributions made by each author are required at the time of submission of the manuscript.

CLINICAL TRIAL

PJP considers the publication of results of all randomized control trials (RCT) if the ICMJE recommendations are followed (http://www.icmje.org/icmje-recommendations.pdf). A registration number will have to be provided with the manuscript and should be noted after the end of the abstract. The ICMJE uses the World Health Organization (WHO) definition of a clinical trial, which is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". This definition includes phase I to IV trials. The ICMJE defines health-related interventions as "any intervention used to modify a biomedical or health-related outcome" and health-related outcomes as "any biomedical or health-related measures obtained in patients or participants". Authors who are unsure whether their trial needs registering should consult the ICMJE FAQs for further information. (www.who.int/ictrp/network/primary/en/index.html).

The Drug Regulatory Authority of Pakistan (DRAP) also provides approval and trial numbers for clinical trials involving drugs or appliances (http://www.dra.gov.pk/)

CONFLICT OF INTEREST

A sample definition by World Association of Medical Editors (WAME) states that conflict of interest to exists when a participant in the publication process (author, peer reviewer, or editor) has a competing interest that could unduly influence (or be reasonably seen to do so) his or her responsibilities in the publication process."

Any conflict of interest should be declared by all authors. This may include grants or honorarium, credits and promotions, memberships or any personal or professional relationships which may appear to influence the manuscript. Such competing interests are not unethical but should be declared.

Authors should state the conflict of interest clearly in the submission statement form. This statement should also appear at the end of the text before the references. If there are no conflicts of interests, the authors should state, none to declarer.

 ANIMAL-OR PLANT-BASED STUDIES

Animal-or plant-based studies, or research will not be considered for processing or publication in the PJP.

CONSENT TO PARTICIPATE

For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. For manuscript reporting studies involving vulnerable groups (for example unconscious patients) where there is the potential for coercion (for example prisoners) or where consent may not have been fully informed, manuscripts will be considered at the editors’ discretion. In the case of articles describing human transplantation studies, authors must include a statement declaring that no organs/tissues were obtained from prisoners and must also name the institution(s)/clinic(s)/department(s) via which organs/tissues were obtained.

For all manuscripts that include details, images, or videos relating to an individual person, written informed consent for the publication of these details must be obtained from that person (or their parent or legal guardian in the case of children under 18). If the person has died, consent for publication must be obtained from their next of kin. The manuscript must include a statement that written informed consent for publication was obtained. The consent form must state that the details/images/videos will be freely available on the internet and may be seen by the general public. The consent form must be made available to the Editor if requested, and will be treated confidentially.

 In cases where images are entirely unidentifiable and there are no details on individuals reported within the manuscript, consent for publication of images may not be required. The final decision on whether consent to publish is required lies with the Editor.

MANUSCRIPT PREPARATION GUIDELINES FOR AUTHORS

Pakistan Journal of Pathology (PJP) is the official journal of Pakistan association of Pathologists. Acceptance criteria for all research papers and review articles are based on the quality and originality of the research and its clinical and scientific significance to our readership.

 

Undertaking

The undertaking must be signed by all authors and must contain following statements

  • The material submitted for publication is, original and has not been submitted for publication
  • Co-authors qualify authorship and share the responsibility of contents in manuscript.
  • The research has been approved by ethical committee, and there is no conflict of interest.

 ARTICLE CATEGORIES

The following types of manuscripts are accepted at PJP.

1.     Original article

            Format requirements are;

          A.    Title page

          The title page of the manuscript should include:

          (1)        Title: Should be concise and self-descriptive.

          (2)        Authors: First, middle and last name of each author in sequence of authorship           merit.

          (3)        Affiliation for each author, with the name of department and institution.

          (4)        Corresponding address, cell number, and e mail address of any of first three           authors.

          (5)        A short running head or foot line of no more than 40 characters

          B.          Abstract: Abstract should not be of more than 250 words, it must be structured in headings as objective, material and methods, results and conclusion. Also include 3-5 key words relating to the article subject as abbreviated in the Index -Medicus.

          C.          Material and Methods: Describe the type, duration and place of study. Summarize the demographic data of the subjects. Provide brief descriptions for methods along-with references. Identify all drugs and chemicals used, including generic name, dose and route of administration. Reports of randomized clinical trials should present information on all major study elements and protocols. Describe statistical methods used and specify computer program employed for this purpose.

          D.          Results: Present results in logical sequence in the text, tables, and illustrations. Do not repeat text data in the tables or illustrations.

          E.         Discussion: Justify result findings sequentially one by one. While justifying the findings, cite references that support or negate the findings of your study in a logical way. Compare your findings with other similar studies carried out locally and internationally. In this section limitation of study, recommendations, and conclusions drawn must be clearly mentioned.

          F.         References: References should be cited in consecutive numerical order at first mentioned in the text and designated by the reference number in parenthesis. The references must be written in Vancouver style. A few examples are given below:

                    (1)        For journal articles, list the first six authors only and add, et al. for the                  others. For example:  Guilarde AO, Turchi MD, Siqueira JBJr, Mochan DP, Tersi NL,                    Mouchan L, et al. Dengue hemorrhagic fever in adults: clinical outcome related to                   the serotypes. J Infect Dis. 2012; 197: 817-24.

                    (2)        For books and book chapters, follow as: DeGroot IJ. Evaluation of                            adrenal function and adrenal disease. In: DeGroot L, Stanbury J B, eds. The thyroid                 and its diseases. 5th ed. New York: Wiley, 1985, pp 199-258.

                    (3)        Publications in press follow as:  Benner AI. Molecular mechanisms of                         alcohol in addiction. N Engl J Med. In press 1999.

                    (4)        Journal article in electronic form, follow as: Cosby AI. Factors in the -                   emergence of communicable diseases. Emerg Infect Dis [serial online] 1995 Jan-Mar               [cited 2000 July 5], Computerized Educational Systems, 2000.

                    (5)        Monograph in electronic form, follow asCDI, clinical dermatology                       illustrated [monographs on CD-ROM] Reeves JRT, Maibach H. CMEA Multimedia                     group, producers 2nd ed. Version 2.0. San Diego: CMEA, 1995.

                    (6)        Conference proceedings follow as: Kimura J, Shibasaki H, editors. Recent              advances in clinical neurophysiology. Proceedings of the 10th International Congress              of EKG and Clinical Neurophysiology, 2000 Oct 19-25, Kyoto, Japan. Amsterdam:                     Elsevier, 1996.

                    (7)        Dissertation, follow as: Webster SJ. Post-hospital general health care the               elderly's access and utilization [Thesis]. St. Louis (MO): Washington Univ., 1995.

                    (8)        Volume with supplement, follow as: Lolti HM, Chong AR. Risk                                assessment of Codmium carcinogenicity and occupational skin cancer. Global                        Health Perspect, 1999; 102 Suppl 1:274-94.

          G.          Tables

           Type each table double-spaced on a separate page. Tables should be self-explanatory            and should supplement, not duplicate the text. Each table must be cited in                              consecutive numerical order in the text.

          H.      Illustrations and legends

           Illustrations should clarify and augment the text. Submit two complete sets of glossy              illustrations. No hand drawn art will be accepted. Each illustration must be numbered            and cited in consecutive order in the text. Legends for illustrations should be concise            and should not repeat the text. Legends should be typed double-spaced. Each figure            should be cited in consecutive numerical order in the text. Give the figures a number              following the word Figure. Use letters to designate parts of illustrations (e.g, A, B, C)              and describe each part clearly in the legend. Any letter designations or arrows                       appearing on the illustration should be identified and described fully.

          I.          Letter from Institutional Review Board / Ethical Review Committee 

           Authors are required to send letter from Institutional Review Board / Ethical Review                Committee along with Original articles and Case reports.

          J.          Permission Letter from Med Dte GHQ (Only for Army Serving Doctors)

           Med Dte GHQ permission letter is mandatory for all army serving doctors at the time            of article/ case / report submission.

          K.          Processing / Publication Fee

           The processing fee of Rs. 3000/- (non-refundable) is to be paid at the time of                       submission of the article through demand/bank draft payable in the favor                             of Commandant AFIP account. It is further intimated that authors` will have to                      pay Rs. 5,000/- as publication charges/ fee, if the article is accepted for publication.                The publication charges for case report and short communication will be half of the              above charges. Research Protocol will be published with the same publication                         charges as that of case report. (Payable before issuance of acceptance letter).

           L.           Journal Subscription Fee

                          >    Single Issue: Rs. 500/-

                          >  Annual Subscription Rs. 2000/-

2.          Review Articles

A review article should consist of critical overview/analysis of a topic of interest                     providing the background and recent developments with reference to original                       literature. It should not exceed 4000 words with maximum 50 references and should              have an abstract of no more than 250 words with 3 to  6 key words.

3.           Case Reports

PJP accepts academic and unusual reports of clinical cases. Case reports should not                exceed 1800 words with 10 -15 references and maximum five tables / figures / photomicrographs. Case reports should be prepare in accordance to the CARE checklist (https://www.care-statement.org/resources/checklist) and attach the filled checklist with case reports.

4.           Case Series

A group or series of case reports involving patients who were given similar treatment. Reports of case series usually contain detailed information about the individual patients. This includes demographic information (for example, age, gender, ethnic origin) and information on diagnosis, treatment, response to treatment, and follow-up after treatment.

5.           Short Communication/ Short Report

These are written communications in which a manuscript explains the study done on the small number of populations with restricted outcome and setting. Similar to short communication short reports are brief reports in which a manuscript explains the study done on the small number of populations with restricted outcomes and settings. Short communication should be complete work, not merely a preliminary report. It should not exceed more than 2000 words with maximum two figures / tables with an abstract of no more than 200 words and 12-15 references

6.           Letters to the Editor

A letter sent to the editor to address an area of concern or reporting early results of a new research.

MANUSCRIPT SUBMISSION

  • Go to the Pak J Pathol official website: https://www.pakjpath.com/
  • Click ‘make a submission’ tab on Pak J Pathol website.
  • Please read checklist and make sure that no point in the checklist is missing
  • Click ‘register’ if you are submitting to Pak J Pathol for the first time. If you are already registered with Pak J Pathol then click ‘login’.
  • A new page will open once you click ‘register’. Enter the required information in the given fields. Pakistan Journal of Pathology requests all its authors to register themselves with Pak J Pathol as reviewer by clicking ‘Yes, request the reviewer role’ available at the bottom of ‘registration’ page. After clicking on ‘register’ a new page will open.
  • Please click ‘make a new submission’ on this page
  • A new page will open, with 5 tabs on the top.
  • Start,
  • Upload submission,
  • Enter metadata,
  • Confirmation,
  • Next steps. You will be in ‘start’ tab.
  • In ‘Section’ dropdown list, select the appropriate option. Please make sure that all the ‘submission requirements’ are fulfilled. Tick the checkbox against each requirement. Note: if any of the requirement is not fulfilled, and you put a tick mark against it, you still will be able to proceed and complete your submission process but the submission will be declined automatically by the system. In ‘comments for the editor’ area you can write your comments, however, it is optional. Under ‘Acknowledge the copyright statement’ tick the checkboxes against both the options. Click ‘save and continue’
  • Now you will be in ‘upload submission’ tab. A dialogue box will open and here you can upload all your files (article text, title page, ERC/IRB approval letter, undertaking, processing fee) one by one. Click ‘save and continue’.
  • Now you will be in ‘enter metadata’ tab. You may leave ‘prefix’ field blank. Write title of the article in ‘title’ field. Write running/short title in ‘subtitle’ field (you may leave it blank). Copy/paste abstract in abstract area. In ‘list of contributors’ sections, click ‘add contributor’ (if you have other authors with you). A new dialogue box will open. Please fill in details of each contributor (author). Please do give affiliation of each contributor. Additional details about the contributor can be given in the text box below. For ‘contributor’s role’ please click ‘author’. Please tick the check box ‘Principal contact for editorial correspondence’ for corresponding author only. Lower checkbox ‘Include this contributor in browse lists?’ will remain ticked for all the authors. Click ‘save’ and repeat the same process for all the authors one by one. Please add all the authors as per the pre-decided sequence. Please fill the ‘languages’, ‘subjects’, ‘discipline’ and ‘key words’ fields appropriately. These fields are essential. Each key word MUST be added SEPARATELY one by one instead of 'copy/paste' all the key words together. Please click ‘save and continue’.
  • You are now in ‘confirmation’ tab. Please click ‘finish submission’. Congratulations, you have successfully completed your submission to Pak J Pathol.
  • You can track the status/progress of your article through editorial process any time by logging into your account.

 SCIENTIFIC MISCONDUCT

Regarding any matter associated with scientific misconduct, Pak J Pathol follows the guidelines mentioned by  Committee on Publication Ethics (COPE) https://publicationethics.org/misconduct, and The International Committee of Medical Journal Editors (ICMJE) https://www.icmje.org/icmje-recommendations.pdf .

Following these guidelines, Pak J Pathol can handle scientific misconducts like falsification of data, plagiarism, redundant and duplicate publication, simultaneous submission, improprieties of authorship, misappropriation of the ideas of others and violation of generally accepted research practices. Others can be material failure to comply with legislative and regulatory requirements affecting research, inappropriate behavior in relation to misconduct, Salami slicing (or salami publication) and plagiarism check. Their details are mentioned below:

  • Falsification of data: This ranges from fabrication to deceptive reporting of findings and omission of conflicting data, or willful suppression and/or distortion of data.
  • Plagiarism, redundant and duplicate publication: The appropriation of the language, ideas or thoughts of another without crediting their true source and representation of them as one’s own original work.
  • Simultaneous submission: This occurs when a person submits a paper to different publications at the same time, which can result in more than one journal publishing that particular paper. Articles submitted for publication must be original and must not have been submitted to any other journal.We require authors to disclose any details of related papers in press, including translations  
  • Improprieties of authorship: Improper assignment of credit, such as excluding others, misrepresentation of the same material as original in more than one publication, inclusion of individuals as authors who have not made a definite contribution to the work published or submission of multi-authored publications without the concurrence of all authors.
  • Misappropriation of the ideas of others: an important aspect of scholarly activity is the exchange of ideas among colleagues. Scholars can acquire novel ideas from others during the process of reviewing grant applications and manuscripts. However, improper use of such information can constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results. A lack of declaration of competing interests and of funding/sponsorship, and other failures of transparency.
  • Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biological or chemical materials.
  • Inappropriate behaviour in relation to misconduct: This includes unfounded or knowingly false accusations of misconduct, failure to report known or suspected misconduct, withholding of information relevant to a claim or misconduct and retaliation against persons involved in the allegation or investigation.
  • Salami slicing (or salami publication):It is described as unnecessary splitting of findings from a single study across several publications. Salami slicing is considered a form of redundant publication. We do not accept publications where we suspect salami slicing has occurred, as these publications have the potential to skew the scientific record and create biases in the results of meta-analyses. All submitted articles will be assessed for potential salami slicing by our editorial team as part of our standard checks. Studies that share significant similarities in the hypotheses, population, and methods should usually be presented to the readers in a single paper. If you believe that you have legitimate grounds to submit multiple publications based on the same study, we ask that you inform the editorial office about any and all potentially overlapping papers (published or unpublished). For further information about best practice please refer to the ICMJE guidance on overlapping publications.

Plagiarism detection: Pak J Pathol checks the similarity index by using plagiarism software prior publication of manuscripts. Submission to Pak J Pathol implies that the work described has not been accepted for publication elsewhere, that it is not under consideration for publication elsewhere and does not duplicate material already published.

POLICY FOR COMPLAINTS HANDLING

This procedure applies to complaints that relate to content, procedures or policies that are the responsibility of Pak J Pathol or our editorial staff. Complaints may provide an opportunity and a spur for improvement, and so we aim to respond quickly, courteously, and constructively. The procedure outlined below aims to be fair to those making complaints and those complained about. Complaints must relate to content or a procedure that was the responsibility of Pak J Pathol or our editorial staff. We define a complaint as: ‘anything defined as a complaint by the complainant’ and ‘anything we believe goes beyond an expression of disagreement with a decision and identifies a perceived failure of process or severe misjudgment. For that Pak J Pathol appeals procedure will be opted to make a complaint. It should be directly emailed to [email protected]

  • All complaints will be reviewed initially by our editorial team.  
  • This team will direct the complaint to the relevant member of the editorial or publishing staff and escalate if required.
  • In the case that this initial response is felt to be insufficient, the complainant can request that their complaint is escalated to a more senior member of the team.
  • If the complainant remains unhappy, complaints may be escalated to Pak J Pathol Chief Editor, whose decision is final in view to satisfy and justify the complaint.

 POST- PUBLICATION DISCUSSIONS AND CORRECTIONS POLICY

Correction Policy:

Erratum is an error that affects the veracity of the published paper, the reputation of the authors. Errata are published as a distinct article. An erratum should be published in the case of a serious mistake or a factual error or omission in the methods, results, or conclusions. To warrant an erratum the scientific error must be serious enough to affect the replication and interpretation of results.

Cases that warrant an erratum:

  • A figure was not explained correctly.
  • Incorrect results were included in a table.
  • An author is accidentally missed out.

A notice of correction will be issued by Pak J Pathol to article and correct considerable errors that appear in online articles when these errors considerably affect the content or understanding of the work reported (e.g., error in data presentation) or when the error affects the publication’s metadata (e.g., misspelling of an author’s name). In these cases, Pak J Pathol will publish a correction that will be linked to the original article.

We expect authors to inform the journal’s office of any errors they have observed (or have been informed of) in their article once published.

Removal of Published Content:

In exceptional circumstances, the Pak J Pathol reserves the right to remove a paper from Pak J Pathol online platforms. This may happen when:

  • Pak J Pathol has been advised that content is defamatory;
  • Infringes a third party’s intellectual property right, right to privacy or another legal right;
  • It poses an immediate and serious risk to health if acted upon.

Criteria for the Emergency Takedown:

The emergency takedown will be happened if:

  • The publication of a paper contains a photograph in which a particular individual can be identified;
  • The paper includes the personal identifying information of an individual that lead to an individual being easily identified.

Addenda:

An addendum is a notification to add information to a published paper. It should be noted that the addenda do not contradict the original publication and are not used to fix the error. For the errors, the Pak J Pathol will publish a correction notice. Actually, if the author needs to update or add some key information then, they can publish an addendum. According to the Pak J Pathol policies, the addenda may be peer-reviewed and are normally subject to oversight by the chief editor.

PRIVACY STATEMENT

The names and email addresses entered in this journal site will be used exclusively for
the stated purposes of this journal and will not be made available for any other purpose
or to any other party

ETHICAL APPROVAL OF RESEARCH

Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption). Further information and documentation to support this should be made available to the Editor on request. Manuscripts may be rejected if the Editor considers that the research has not been carried out within an appropriate ethical framework. In rare cases, the Editor may contact the ethics committee for further information.

LICENSE TERMS

The Pakistan Journal Pathology follows "CC BY NC" creative commons licensing. 

PUBLICATION TIMELINES

Pak J Pathol is a quarterly medical journal. Timelines for print and online publications are as under:-

Issue No

Month

Date

1

January - March

31st March

2

April - June

30th June

3

July - September

30th September

4

October - December

31st December